Glaucoma and Cataract Department, Enshi Huiyi Ophthalmic Hospital, Enshi, Hubei 445000, China.
Ophthalmologic Center, Hubei General Hospital, Wuhan, Hubei 430061, China.
Comput Math Methods Med. 2022 Jun 28;2022:1041558. doi: 10.1155/2022/1041558. eCollection 2022.
To investigate the effects of recombinant human epidermal growth factor eye drops combined with phacoemulsification on short- and long-term visual acuity recovery and related dry eye complications in patients with senile cataract.
Sixty patients with senile cataract cured from January 2019 to January 2021 were enrolled in our hospital. The patients in the control group were arbitrarily assigned into the control and the research group. The former group received phacoemulsification, and the latter group received recombinant human epidermal growth factor (RhEGF) eye drops combined with phacoemulsification. The curative effect, the incidence of xerophthalmia, short-term and long-term vision improvement, changes of corneal endothelial cells, serum factors, and life quality scores were compared.
The effective rate of the research group was 90.00%, and the effective rate of the control group was 66.67%; the curative effect of the research group was higher than that of the control group ( < 0.05). The incidence of dry eye in the research group was lower than that in the control group ( < 0.05). The short-term and long-term visual acuity improvement effect of the research group was better than that of the control group ( < 0.05). After treatment, the density of corneal endothelial cells in the research group was higher than that in the control group, while the proportion of hexagonal cells and the coefficient of variation of corneal endothelial cells in the research group were lower than those in the control group ( < 0.05). After treatment, IL-6 and TNF- in the research group were lower than those in the control group ( < 0.05). Compared with the control group, the physical function, psychological function, social function, and healthy self-cognition scores of the research group were all lower ( < 0.05).
Cataract is the leading cause of blindness in the world. With the continuous improvement of cataract phacoemulsification technology, the incidence of some serious complications has gradually lessened. Xerophthalmia is one of the most obvious and predictable complications after cataract surgery and may affect the recovery of postoperative visual acuity. Recombinant human epidermal growth factor eye drops can effectively enhance the visual acuity of patients, promote the curative effect, and strengthen the life quality.
研究重组人表皮生长因子滴眼液联合超声乳化术对老年性白内障患者短期和长期视力恢复及相关干眼并发症的影响。
选取我院 2019 年 1 月至 2021 年 1 月收治的 60 例老年性白内障患者，将其随机分为对照组和观察组，各 30 例。对照组患者接受超声乳化术治疗，观察组患者接受重组人表皮生长因子（RhEGF）滴眼液联合超声乳化术治疗。比较两组患者的疗效、干眼发生率、短期和长期视力改善情况、角膜内皮细胞变化、血清因子及生活质量评分。
观察组患者的治疗总有效率为 90.00%，高于对照组的 66.67%（<0.05）。观察组患者的干眼发生率低于对照组（<0.05）。观察组患者的短期和长期视力改善效果优于对照组（<0.05）。治疗后，观察组患者的角膜内皮细胞密度高于对照组，而六边形细胞比例及角膜内皮细胞变异系数均低于对照组（<0.05）。治疗后，观察组患者的白细胞介素 6（IL-6）和肿瘤坏死因子-α（TNF-α）水平低于对照组（<0.05）。与对照组相比，观察组患者的生理功能、心理功能、社会功能及健康自我认知评分均更低（<0.05）。
白内障是全球致盲的首要原因。随着白内障超声乳化技术的不断进步，一些严重并发症的发生率逐渐降低。白内障术后最明显和可预测的并发症之一是干眼，可能会影响术后视力的恢复。重组人表皮生长因子滴眼液能有效提高患者的视力，促进疗效，增强生活质量。
